A detailed history of Barclays PLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Barclays PLC holds 287,591 shares of BMRN stock, worth $18.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
287,591
Previous 287,591 -0.0%
Holding current value
$18.9 Million
Previous $20.2 Million -0.0%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

SELL
$69.02 - $93.84 $57.3 Million - $78 Million
-830,789 Reduced 74.29%
287,591 $20.2 Million
Q2 2024

Aug 14, 2024

SELL
$74.43 - $92.22 $308 Million - $381 Million
-4,136,140 Reduced 78.72%
1,118,380 $92.1 Million
Q1 2024

May 15, 2024

SELL
$83.81 - $99.0 $2.88 Million - $3.4 Million
-34,373 Reduced 0.65%
5,254,520 $459 Million
Q4 2023

Feb 15, 2024

SELL
$76.22 - $98.51 $21.7 Million - $28 Million
-284,264 Reduced 5.1%
5,288,893 $510 Million
Q3 2023

Nov 07, 2023

BUY
$85.07 - $94.48 $248 Million - $275 Million
2,911,886 Added 109.42%
5,573,157 $493 Million
Q2 2023

Aug 03, 2023

BUY
$86.68 - $100.3 $91.6 Million - $106 Million
1,056,445 Added 65.83%
2,661,271 $231 Million
Q1 2023

May 04, 2023

SELL
$87.74 - $117.27 $33.1 Million - $44.3 Million
-377,663 Reduced 19.05%
1,604,826 $156 Million
Q4 2022

Feb 13, 2023

SELL
$80.93 - $108.63 $21.9 Million - $29.4 Million
-270,314 Reduced 12.0%
1,982,489 $205 Million
Q3 2022

Nov 03, 2022

BUY
$82.16 - $96.94 $7.16 Million - $8.45 Million
87,163 Added 4.02%
2,252,803 $191 Million
Q2 2022

Aug 12, 2022

BUY
$71.48 - $86.85 $143 Million - $174 Million
2,001,395 Added 1218.54%
2,165,640 $179 Million
Q1 2022

May 16, 2022

SELL
$74.28 - $92.69 $2.53 Million - $3.16 Million
-34,114 Reduced 17.2%
164,245 $12.7 Million
Q4 2021

Feb 14, 2022

SELL
$71.72 - $91.47 $772,496 - $985,223
-10,771 Reduced 5.15%
198,359 $17.5 Million
Q3 2021

Nov 09, 2021

BUY
$74.77 - $85.47 $1.13 Million - $1.29 Million
15,055 Added 7.76%
209,130 $16.2 Million
Q2 2021

Aug 13, 2021

BUY
$75.51 - $84.79 $696,126 - $781,679
9,219 Added 4.99%
194,075 $16.2 Million
Q1 2021

May 13, 2021

SELL
$74.73 - $90.69 $7.08 Million - $8.6 Million
-94,798 Reduced 33.9%
184,856 $14 Million
Q4 2020

Feb 11, 2021

BUY
$72.61 - $90.2 $4.13 Million - $5.13 Million
56,826 Added 25.5%
279,654 $24.5 Million
Q3 2020

Nov 12, 2020

SELL
$71.87 - $131.03 $4.52 Million - $8.25 Million
-62,955 Reduced 22.03%
222,828 $17 Million
Q2 2020

Aug 12, 2020

SELL
$79.55 - $124.22 $1.06 Million - $1.65 Million
-13,284 Reduced 4.44%
285,783 $35.3 Million
Q1 2020

May 13, 2020

SELL
$71.37 - $96.85 $7.39 Million - $10 Million
-103,556 Reduced 25.72%
299,067 $25.3 Million
Q4 2019

Feb 10, 2020

BUY
$64.27 - $86.37 $11 Million - $14.7 Million
170,459 Added 73.42%
402,623 $34 Million
Q3 2019

Nov 14, 2019

SELL
$67.4 - $85.11 $12.5 Million - $15.8 Million
-185,826 Reduced 44.46%
232,164 $15.6 Million
Q2 2019

Aug 14, 2019

BUY
$80.35 - $93.9 $10.4 Million - $12.2 Million
129,797 Added 45.04%
417,990 $35.8 Million
Q1 2019

May 15, 2019

BUY
$84.2 - $98.62 $2.75 Million - $3.23 Million
32,717 Added 12.81%
288,193 $25.6 Million
Q4 2018

Feb 14, 2019

SELL
$80.14 - $106.07 $10.8 Million - $14.3 Million
-134,679 Reduced 34.52%
255,476 $21.8 Million
Q3 2018

Nov 14, 2018

SELL
$93.92 - $105.72 $9.87 Million - $11.1 Million
-105,106 Reduced 21.22%
390,155 $37.8 Million
Q2 2018

Aug 14, 2018

BUY
$76.01 - $99.03 $10.1 Million - $13.1 Million
132,231 Added 36.42%
495,261 $46.7 Million
Q1 2018

May 15, 2018

BUY
$77.67 - $92.63 $578,253 - $689,630
7,445 Added 2.09%
363,030 $29.4 Million
Q4 2017

Feb 14, 2018

BUY
$80.76 - $95.13 $2.26 Million - $2.66 Million
27,936 Added 8.53%
355,585 $31.7 Million
Q3 2017

Nov 14, 2017

BUY
$80.6 - $94.95 $26.4 Million - $31.1 Million
327,649
327,649 $30.5 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.2B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.